This hypothesis pointed to a possible future therapeutic paradigm that epigenetic modulator such as HDAC inhibitor may activate autologous and adoptive anti-leukemia CTL responses through increasing CTA expression [26]. This evidence concerns the gene HDAC9 and leukemia.